The net asset value (NAV) of EfTEN United Property Fund units was 11,30 euros at the end of August, up 0,6% month-on-month. The fund earned 166 thousand euros in net profit in August and 2,01 million euros in net profit in the first eight months of 2025 (470 thousand euros in the same period last year). In August, the renovation of a residential rental apartment building in Riga, where the fund is invested through the EfTEN Residential Fund, was completed. As a result, 102 renovated apartments were added to ...

MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $180 million to the Company, before pla ...

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Innate Pharma Reports First Half 2025 Business Update And Financial Results. ...

Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-treatment remissions Well tolerated with a favorable safety profile consistent with the IL-23p19 class EVERLAST-A Phase 2a trial enrollment ongoing with data expected 2H 2026 MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developi ...

EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary endpoints in biologic-naïve patients compared to placebo at week 16Dual-target Nanobody® VHH inhibiting TNF and OX40L being explored across a range of immune-mediated diseasesReaffirms Sanofi’s commitment to addressing underlying inflammation across complex, heterogeneous chronic skin diseases Paris, September 1 ...

TextMagic AS (registry code 16211377, hereinafter the “Company”) Management Board announces this draft resolution of the shareholders with the purpose of adopting the resolution of the shareholders without calling a meeting in accordance with clause 2991 of the Commercial Code to distribute profit to the shareholders. In order to optimize costs, the Management Board of the Company has decided to adopt the resolution without convening a meeting and to not organise a general meeting of shareholders. Draft re ...

La Hulpe, Belgium – 17 September 2025, 7:00 a.m. CEST – Banqup Group SA, formerly Unifiedpost Group SA, (Euronext: BANQ) (Banqup, Company), a leading provider of integrated business communications solutions, today announced a strategic partnership with Deloitte Belgium for their accountancy clients. Under this agreement, Deloitte Belgium will adopt Banqup as the digital platform for day-to-day accounting operations across thousands of its clients, ranging from SMEs to large enterprises. Through this colla ...

EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary endpoints in biologic-naïve patients compared to placebo at week 16Dual-target Nanobody® VHH inhibiting TNF and OX40L being explored across a range of immune-mediated diseasesReaffirms Sanofi’s commitment to addressing underlying inflammation across complex, heterogeneous chronic skin diseases Paris, September 1 ...

- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARIâ"¢ for the treatment of moderate-to-severe acne - SAN DIEGO, CA / ACCESS Newswire / September 17, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced the presentation of an abstract from its XYNGARIâ"¢ (also known as DMT310) Phase 3 Spongilla Treatment of Acne Research clinical trial (STAR-1) will ...

Nothing that the Trump administration is doing to the Fed will make it any more difficult for the profit machines that power the stock market to earn cash. ...